1.
Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley RG, Barker J, Wang M, Vanvoorden V, Szilagyi B, Ciaravino V, Paul C. Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial. J of Skin [Internet]. 2022Nov.16 [cited 2023Feb.1];6(6):s65. Available from: https://jofskin.org/index.php/skin/article/view/1820